Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
5.83
-0.02 (-0.34%)
Apr 9, 2026, 9:11 AM EDT - Market open
Silence Therapeutics Employees
Silence Therapeutics had 88 employees as of December 31, 2025. The number of employees decreased by 28 or -24.14% compared to the previous year.
Employees
88
Change (1Y)
-28
Growth (1Y)
-24.14%
Revenue / Employee
$6,352
Profits / Employee
-$1,006,955
Market Cap
275.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 88 | -28 | -24.14% |
| Dec 31, 2024 | 116 | 7 | 6.42% |
| Dec 31, 2023 | 109 | -13 | -10.66% |
| Dec 31, 2022 | 122 | 17 | 16.19% |
| Dec 31, 2021 | 105 | 40 | 61.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Adagene | 138 |
| Foghorn Therapeutics | 106 |
| C4 Therapeutics | 104 |
| Alector | 103 |
| Editas Medicine | 87 |
| Cybin | 50 |
| Protara Therapeutics | 46 |
SLN News
- 5 weeks ago - Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 months ago - Silence Therapeutics Announces Leadership Changes - Business Wire
- 5 months ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 5 months ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 months ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 7 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 8 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 10 months ago - Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera - Business Wire